Rosenne Ella, Shakhar Guy, Melamed Rivka, Schwartz Yossi, Erdreich-Epstein Anat, Ben-Eliyahu Shamgar
Neuroimmunology Research Unit, Department of Psychology, Tel Aviv University, Tel Aviv 69978, Israel.
Brain Behav Immun. 2007 May;21(4):395-408. doi: 10.1016/j.bbi.2006.12.002. Epub 2006 Dec 16.
Perioperative suppression of NK activity has been suggested to compromise host resistance to tumor progression. Here, we sought to develop a clinically applicable preoperative regimen to prevent immunosuppression and promotion of metastasis by stress or surgery. The synthetic ds-RNA, poly I-C, was used in vivo in F344 rats, based on its alleged in vitro ability to protect immunocytes from suppression by cAMP elevating agents. Different regimens of poly I-C were studied in controls and in rats subjected to a pharmacological stressor, swim stress, or surgical stress. Resistance to lung experimental metastasis of the syngeneic non-immunogenic MADB106 mammary adenocarcinoma was assessed. Numbers of circulating and marginating-pulmonary NK cells and their cytotoxicity against the MADB106 and YAC-1 target lines were also studied. Our findings established a regimen of repeated low-dose poly I-C administration with minimal side effects (0.2mg/kg i.p. 5, 3, and 1day before tumor inoculation). This regimen, while hardly affecting resistance levels in non-stressed animals, prevented all stressors from promoting metastases. These beneficial effects occurred in the presence of a primary tumor and in both sexes. Poly I-C increased the numbers of NK cells, and, on a per NK cell basis, while not increasing cytotoxicity, profoundly protected marginating-pulmonary NK cells from suppression by surgery. This study suggests a non-toxic clinically translatable prophylactic use of poly I-C to target the critical perioperative period. By increasing the number of marginating-pulmonary NK cells, and by transforming them into a mode of resistance to immunosuppression, this approach may reduce postoperative metastasis in cancer patients.
围手术期自然杀伤细胞(NK)活性受到抑制,这被认为会损害宿主抵抗肿瘤进展的能力。在此,我们试图开发一种临床适用的术前方案,以预防应激或手术导致的免疫抑制和转移促进。基于其在体外据称具有保护免疫细胞免受cAMP升高剂抑制的能力,合成双链RNA聚肌胞苷酸(poly I-C)在F344大鼠体内使用。在对照组以及接受药理学应激源、游泳应激或手术应激的大鼠中研究了不同的poly I-C给药方案。评估了对同基因非免疫原性MADB106乳腺腺癌肺实验性转移的抵抗力。还研究了循环和肺边缘NK细胞的数量及其对MADB106和YAC-1靶细胞系的细胞毒性。我们的研究结果确定了一种重复低剂量poly I-C给药方案,其副作用最小(在接种肿瘤前5天、3天和1天腹腔注射0.2mg/kg)。该方案在几乎不影响非应激动物抵抗力水平的情况下,可防止所有应激源促进转移。这些有益效果在存在原发性肿瘤的情况下以及在两性中均出现。Poly I-C增加了NK细胞的数量,并且在单个NK细胞的基础上,虽然没有增加细胞毒性,但能显著保护肺边缘NK细胞免受手术抑制。本研究表明,poly I-C可用于围手术期关键时期的无毒临床转化预防性应用。通过增加肺边缘NK细胞的数量,并将它们转化为抵抗免疫抑制的模式,这种方法可能会减少癌症患者术后的转移。